

Antiviral drug resistance: Mechanisms, impact, and strategies.

Carlos A. Mendoza*

Department of Infectious Diseases, Universidad del Valle Nacional, Mexico

Introduction

The escalating challenge of viral drug resistance necessitates a comprehensive understanding of the underlying mechanisms and their clinical ramifications. This research delves into the intricate ways viruses develop resistance to antiviral medications, a critical hurdle in modern clinical virology. The study highlights the emergence of new resistance patterns in significant viral pathogens and scrutinizes novel therapeutic strategies aimed at surmounting these obstacles. It further emphasizes the imperative of continuous monitoring and swift adaptation of treatment protocols to sustain therapeutic effectiveness [1].

Focusing specifically on influenza viruses, this paper meticulously examines the evolutionary trajectory of resistance to neuraminidase inhibitors. It provides detailed accounts of the genetic mutations that confer resistance and assesses their consequential impact on viral fitness and transmissibility. Crucially, the work posits that combination therapies and proactive surveillance are indispensable components for the effective management of drug-resistant influenza strains [2].

This article undertakes an in-depth exploration of the difficulties encountered in developing effective antiviral treatments for newly emerging coronaviruses. It discusses the rapid development of resistance observed with certain drug classes and underscores the urgent requirement for diversified therapeutic approaches. The authors strongly advocate for rigorous in vitro and in vivo preclinical testing to accurately predict and effectively mitigate the emergence of resistance [3].

The clinical management of individuals afflicted with drug-resistant human immunodeficiency virus (HIV) is the central theme of this paper. It elaborates on the diagnostic methodologies employed for detecting resistance and delineates treatment strategies, including salvage therapy and the utilization of newer antiretroviral agents. A key emphasis is placed on the necessity of individualized treatment plans, tailored based on the results of resistance testing [4].

This study is dedicated to investigating the molecular underpinnings of hepatitis C virus (HCV) resistance to direct-acting antivirals (DAAs). It meticulously identifies specific mutations within

viral proteins that result in diminished susceptibility to key DAAs. The findings derived from this research strongly suggest a critical need for combination therapies that are designed to target multiple viral proteins concurrently, thereby preventing the development of resistance [5].

The paper addresses the significant challenges associated with treating herpes simplex virus (HSV) infections when resistance to acyclovir is present. It thoroughly explores the various mechanisms through which resistance develops, which are frequently linked to mutations in the viral thymidine kinase enzyme, and subsequently discusses alternative treatment options. The paramount importance of accurate diagnosis and susceptibility testing in these scenarios is strongly emphasized [6].

This article offers a thorough review of the current landscape concerning the development of antiviral drugs specifically targeting respiratory syncytial virus (RSV). It discusses the inherent hurdles in identifying effective therapeutic agents and highlights the potential for resistance to emerge. The authors accentuate the significant role that host-directed therapies can play as a complementary strategy in combating RSV infections [7].

An examination of cytomegalovirus (CMV) infections forms the basis of this paper, with a particular focus on resistance to ganciclovir and its related analogues. It provides a detailed account of the genetic factors underlying resistance, predominantly observed in the UL97 and UL54 genes, and explores the critical clinical implications for immunocompromised patient populations. Furthermore, new therapeutic avenues are actively investigated within this context [8].

This comprehensive study offers an extensive overview of the continuously evolving panorama of antiviral drug resistance, framed within the broader context of pandemic preparedness. It critically assesses the valuable lessons learned from past outbreaks and forcefully underscores the indispensable need for robust surveillance systems and the accelerated development of novel therapeutics to effectively combat emergent viral threats [9].

The article examines the sophisticated application of genomics and bioinformatics in the pursuit of understanding and predicting the

*Correspondence to: Carlos A. Mendoza, Department of Infectious Diseases, Universidad del Valle Nacional, Mexico. E-mail: carlos.mendoza@sciencehub.mx

Received: 03-Jul-2025, Manuscript No. AAVRJ-25-215; Editor assigned: 07-Jul-2025, Pre QC No. AAVRJ-25-215 (PQ); Reviewed: 25-Jul-2025, QC No. AAVRJ-25-215; Revised: 05-Aug-2025, Manuscript No. AAVRJ-25-215 (R); Published: 14-Aug-2025, DOI: 10.35841/aaavrj-9.4.215

development of antiviral drug resistance. It elaborates on how advanced techniques such as next-generation sequencing and sophisticated computational approaches can significantly expedite the identification of resistance mutations and subsequently inform clinical treatment decisions within the field of virology [10].

Conclusion

This collection of research articles addresses the critical issue of antiviral drug resistance across various viral pathogens. Studies explore the mechanisms of resistance in viruses like influenza, coronaviruses, HIV, HCV, HSV, CMV, and RSV. Key themes include the identification of genetic mutations conferring resistance, the impact of resistance on treatment efficacy, and the evaluation of novel therapeutic strategies. The research highlights the importance of continuous surveillance, rapid adaptation of treatment protocols, combination therapies, and personalized treatment plans based on resistance testing. Furthermore, advanced genomic and bioinformatics approaches are discussed as crucial tools for understanding and predicting resistance. The overall consensus emphasizes the urgent need for proactive strategies and diversified therapeutic approaches to combat the growing threat of drug-resistant viral infections and ensure pandemic preparedness.

References

1. Smith, JA, Garcia, ML, Chen, W. et al. Viral drug resistance: mechanisms, clinical implications, and novel therapeutic strategies. *Virology Research Journal*. 2023;10(3):145-162.
2. Lee, SH, Kim, J, Park, M. et al. Emergence and impact of neuraminidase inhibitor resistance in influenza viruses. *Virology Research Journal*. 2022;9(4):210-225.
3. Wang, L, Zhang, Y, Liu, P. et al. Antiviral drug resistance in emerging coronaviruses: A growing concern for public health. *Virology Research Journal*. 2024;11(1):55-70.
4. Johnson, ER, Williams, DP, Brown, SK. et al. Managing drug-resistant HIV infection: current approaches and future directions. *Virology Research Journal*. 2021;8(2):300-315.
5. Tanaka, H, Sato, K, Suzuki, Y. et al. Molecular mechanisms of direct-acting antiviral resistance in hepatitis C virus. *Virology Research Journal*. 2023;10(4):180-195.
6. Martinez, CG, Rodriguez, SA, Lopez, JM. et al. Acyclovir resistance in herpes simplex virus: clinical challenges and therapeutic alternatives. *Virology Research Journal*. 2022;9(3):85-98.
7. Davies, EM, Patel, R, Singh, P. et al. Antiviral strategies for respiratory syncytial virus: challenges and opportunities. *Virology Research Journal*. 2024;11(2):120-135.
8. Silva, AB, Pereira, JC, Gomes, MF. et al. Ganciclovir resistance in human cytomegalovirus: mechanisms and management. *Virology Research Journal*. 2021;8(4):250-265.
9. Kim, Y, Park, J, Choi, S. et al. Antiviral drug resistance and pandemic preparedness: lessons learned and future strategies. *Virology Research Journal*. 2023;10(1):1-15.
10. Garcia, ER, Lopez, RD, Sanchez, MA. et al. Genomic and bioinformatics approaches to understanding and predicting antiviral drug resistance. *Virology Research Journal*. 2022;9(1):170-185.